O
Odonate Therapeutics Inc
OTC:ODTC
Odonate Therapeutics Inc
OTC:ODTC
Price:
50 000
USD
Market Closed
Market Cap:
$52.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
O
|
Odonate Therapeutics Inc
OTC:ODTC
|
US |
|
California Resources Corp
NYSE:CRC
|
US |
|
H
|
Hercules Site Services PLC
LSE:HERC
|
UK |
|
Sichuan New Energy Power Co Ltd
SZSE:000155
|
CN |
|
S
|
SC Estate Builder Bhd
KLSE:SCBUILD
|
MY |
|
D
|
Douglas Elliman Inc
NYSE:DOUG
|
US |
|
Gogo Inc
NASDAQ:GOGO
|
US |
|
G-Next Inc
TSE:4179
|
JP |
|
C
|
Central Puerto SA
BCBA:CEPU
|
AR |
|
K
|
KPN Real Estate Investment Trust
SET:KPNREIT
|
TH |
|
Farmacias Benavides SAB de CV
BMV:BEVIDESB
|
MX |
|
B
|
Brilliant AG
XBER:BAG
|
DE |
|
Panacea Biotec Ltd
NSE:PANACEABIO
|
IN |
|
Chenming Electronic Technology Corp
TWSE:3013
|
TW |
|
Mandarake Inc
TSE:2652
|
JP |
|
G
|
GBM Resources Ltd
OTC:GBMRF
|
AU |
|
Toyo Wharf & Warehouse Co Ltd
TSE:9351
|
JP |
|
Tata Power Company Ltd
NSE:TATAPOWER
|
IN |
|
Winbond Electronics Corp
TWSE:2344
|
TW |
Relative Value
There is not enough data to reliably calculate the relative value of ODTC.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ODTC
Relative Value
Base Case
Not Available
Multiples Across Competitors
ODTC Competitors Multiples
Odonate Therapeutics Inc Competitors
Odonate Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
O
|
Odonate Therapeutics Inc
OTC:ODTC
|
52.7m USD | 0 | -0.5 | 0.5 | 0.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.1 | 41.5 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.6 | 11.1 | 12.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.5B GBP | 4.9 | 28.1 | 15.6 | 22 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 5.1 | 20.6 | 12.8 | 16.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD | 2.4 | 16.4 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
